A company that sells software to cardiologists grew revenue 48% and raised its full-year outlook for the second quarter in a row. The market’s answer was a 25% gap before the open — and the interesting question is not whether the quarter was good, but how much of the raise rests on a single product line.
Heartflow reported second-quarter 2026 results after Thursday’s close, and $HTFL went from a $31.01 close to roughly $38.90 in pre-market trade, a move of about 25.4%. The headline numbers are unambiguous: revenue of $64.1 million, up 48% year over year, a non-GAAP loss of $0.07 a share against a consensus looking for roughly a $0.19 loss, and full-year revenue guidance lifted to $246–$250 million from the $228–$232 million the company had guided to three months earlier. The results and guidance are covered in the company’s Q2 2026 results release, the guidance detail in Seeking Alpha’s coverage, the earnings-night reaction in Yahoo Finance’s earnings live blog, and the price, share count and volume history at StockAnalysis.
This profile walks through what Heartflow actually sells, what the quarter showed beneath the headline, why the guidance raise is really a story about one newer product, what the patent fight with its closest competitor signals, and what a buyer at this morning’s price is underwriting.
Company snapshot
- Company: Heartflow, Inc. · Ticker: HTFL (Nasdaq Global Select)
- Sector: Healthcare · Medical technology / AI cardiac imaging
- Headquarters: 135 Main Street, San Francisco, California
- CEO: John Farquhar, president and chief executive officer
- Platform: Heartflow One — FFRCT Analysis, RoadMap Analysis, Plaque Analysis
- Listed: IPO priced at $19.00 per share; began trading on Nasdaq August 8, 2025
- Approx. market cap: ~$2.70B on ~86.95M shares · 52-week range: $20.13 – $41.22
- 3-month average volume: ~1.94M shares
Snapshot figures are drawn from the company’s own materials, its IPO announcements and StockAnalysis; the quarterly results are sourced below.
What Heartflow actually sells
Coronary artery disease is diagnosed badly, and expensively. The traditional path for a patient with chest pain runs toward invasive coronary angiography — a catheter threaded into the arteries to see whether a narrowing is actually restricting blood flow. A large share of those procedures find nothing that needs treating. The patient has been through an invasive test anyway.
Heartflow’s proposition is to answer the same question from a CT scan the patient has already had. Its software takes a standard coronary CT angiogram, builds a personalised three-dimensional model of that patient’s coronary arteries, and applies computational fluid dynamics to estimate blood flow through them. The output, FFRCT Analysis, gives the cardiologist a physiological number — is this narrowing actually starving the heart muscle? — without a catheter.
That original product is now one of three sitting on a platform the company calls Heartflow One. RoadMap Analysis provides anatomic visualisation of the coronary arteries. FFRCT Analysis is the blood-flow calculation that built the business. Plaque Analysis characterises the plaque itself — how much there is and what type — which is a different clinical question from whether flow is currently restricted. Plaque is about future risk rather than present ischaemia, and it is the product doing most of the work in this quarter’s numbers.
The economics are attractive because the delivery is asset-light. Heartflow does not manufacture an implant or ship a capital device into a cath lab. A scan is uploaded, processed and returned as an analysis. That is why gross margin sits where it does, and why incremental volume drops through so efficiently.
The numbers behind the morning
| Metric | Q2 2026 | Comparison |
|---|---|---|
| Total revenue | $64.1M | +48% year over year |
| U.S. revenue | $59.6M | +51% year over year |
| Gross margin (GAAP) | 83.0% | vs. 75.5% a year earlier |
| Gross margin (non-GAAP) | 83.3% | +770 basis points |
| Non-GAAP net loss | $0.07 per share | vs. ~$0.19 loss expected |
| FY2026 revenue guidance | $246M – $250M | raised from $228M – $232M |
| FY2026 implied growth | 40% – 42% | — |
| FY2026 Plaque revenue guidance | $29M – $31M | raised |
| FY2026 non-GAAP gross margin | ~82% | — |
| Pre-market reaction | $31.01 → ~$38.90 | +25.4% before the open |
Sources: Heartflow’s August 13, 2026 second-quarter results release; Seeking Alpha and Yahoo Finance coverage of the report; StockAnalysis for price, share count and volume. Adjusted figures are non-GAAP as reported by the company.
Three things stand out once you get past the growth rate. The first is that the gross-margin expansion — roughly 770 basis points to 83.3% — is larger than most software companies manage in a year, let alone a quarter. That comes from two places: automation reducing the human touch required per analysis, and volume leverage over a largely fixed processing cost base.
The second is that U.S. revenue grew faster than total revenue, 51% against 48%. The domestic business is where reimbursement is established and the sales motion is proven, and it is pulling the company along. The corollary is that international remains a small and slower contributor.
The third is the shape of the loss. A $0.07 non-GAAP loss against expectations near $0.19 is a large relative beat, but it is still a loss. Heartflow is closing the gap to profitability through gross-margin expansion and operating leverage rather than through cost cuts — a healthier mechanism, but one that requires growth to continue.
Twelve months of tape
The chart carries a warning the headline does not. HTFL has traded between $20.13 and $41.22 over the past year, and this morning’s $38.90 puts it near the upper end of that band rather than breaking out of it. This is a stock that has already been priced for a good outcome once before. A company with roughly one year of public trading history has not yet shown investors how it behaves through a quarter that disappoints, and the range above tells you how much room the market gives it in both directions.
Why the guidance raise is a Plaque story
The most important sentence in the release is not the revenue line. It is that full-year Plaque Analysis revenue guidance rose to $29–$31 million, and that new account activations for Plaque ran ahead of plan. Management is targeting roughly 1,250 Plaque-activated sites by the end of the year.
Set the numbers side by side. Total guidance went up by about $18 million at the midpoint, from $230 million to $248 million. Plaque is guided to contribute $29–$31 million of the full year. So a product line representing roughly 12% of total revenue is carrying a disproportionate share of the raise and, because it is the higher-margin mix, a disproportionate share of the margin story too.
That is a genuine strategic win. Plaque expands Heartflow’s addressable market beyond patients with symptoms warranting an ischaemia workup toward asymptomatic, high-risk populations — a far larger group. The company has been building clinical evidence toward exactly that, presenting Plaque data at the Society of Cardiovascular Computed Tomography’s 2026 meeting in July and launching the NAVIGATE-PCI registry earlier in the year.
It is also a concentration of risk. A guidance raise driven mainly by early adoption of a newer product is a raise that depends on that adoption curve holding. Site activations are a leading indicator of revenue, not revenue itself; an activated site still has to generate scan volume. If activations keep running ahead of plan, the guidance is conservative. If they flatten, the raise was the peak of the enthusiasm.
The competitive fight, in court
On April 13, 2026, Heartflow filed a patent infringement lawsuit against Cleerly, Inc. in the U.S. District Court for the Eastern District of Texas, asserting that Cleerly’s Ischemia, Plaque Analysis and Compare products infringe six Heartflow patents with priority dates ranging from 2012 to 2018. The complaint seeks a permanent injunction and damages. The filing is described in Heartflow’s own announcement and in trade coverage from MassDevice and Cardiovascular Business.
Read it as a market signal rather than a legal one. Heartflow is the plaintiff, which is the stronger position, and a company that believed its lead was unassailable on product alone would be less likely to spend management attention and legal budget defending it. That the dispute centres on plaque characterisation — precisely the product driving this quarter’s raise — tells you where the competitive pressure is landing. Patent litigation is slow, expensive and uncertain, and injunctive relief against a competitor is a high bar. Nobody should model an outcome here.
The case for caution
Start with the obvious: Heartflow does not make money. The improvement is real and the direction is right, but at $38.90 on roughly 86.95 million shares the company would carry a market value near $3.4 billion, or about fourteen times the midpoint of this year’s guided revenue, for a business still posting losses. That multiple only works if growth stays in the high thirties or better for several more years. Any deceleration re-rates the stock hard, and the 52-week low of $20.13 is a reminder of how much room there is beneath.
Second, the public track record is thin. The company listed in August 2025. There is roughly one year of reported quarters to judge management’s forecasting against. The Q1 report in May also beat and raised, and the stock slipped afterwards anyway — a useful reminder that a good print and a good reaction are different events.
Third, this is a business that depends on other people’s budgets and reimbursement decisions. Revenue arrives one scan at a time through hospitals and imaging centres, and adoption of a newer analysis like Plaque requires clinicians to change a workflow and payers to keep covering it. Neither moves on a quarterly cadence.
Finally, and most immediately: this is a pre-market move. The $38.90 quoted this morning is not a closing price, and a 25% gap on an earnings reaction is exactly the kind of move that fades intraday when the sellers who could not act overnight get their chance.
What to watch next
The near-term tell is whether the gap holds through the first full session — a stock that closes near its pre-market print is being repriced, one that gives most of it back was squeezed. Beyond today, the number that matters is Plaque site activations against that roughly 1,250 year-end target, and whether activated sites convert into scan volume. After that, watch whether gross margin holds above 82% as the mix shifts, and whether international revenue starts to contribute at anything like the U.S. rate. The Cleerly litigation will move on its own slow schedule and is unlikely to produce anything decisive this year.
The bottom line
Heartflow delivered a quarter that was strong on every line that matters: revenue up 48%, U.S. revenue up 51%, gross margin up nearly eight points, a loss less than half what analysts expected, and a full-year outlook raised for the second consecutive quarter. The business model — software analysis of a scan the patient already had — is genuinely differentiated and genuinely asset-light, and the margin structure proves it.
What a buyer at this morning’s price is actually underwriting is narrower than the headline suggests. It is the proposition that Plaque Analysis keeps activating sites ahead of plan, that those sites convert to volume, that growth stays high enough to justify a double-digit revenue multiple on an unprofitable company, and that a competitor Heartflow is currently suing does not take the market it is opening up. That may all prove correct. But it is a bet on the second act, not on the quarter that just printed — and the quarter that just printed is the part already in the price.
Get the next Top Stock Pick in your inbox — free.
Recent Top Stock Picks
- Thoma Bravo Is Taking Accelerant Private for $20.25 a Share — Still Below Its Own IPO Price
- CoreWeave Just Booked $104 Billion of Future Revenue — and Burned $5.7 Billion in a Single Quarter
- A 159-Year-Old Boilermaker Just Became an AI Power Story — and Babcock & Wilcox Jumped 36%
- Cloudflare Jumped ~16% on a 36% Revenue Quarter, 120% Net Retention, and a Raised Full-Year Outlook
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. TopStockPicks.co is not a registered investment advisor and is not a broker-dealer. TopStockPicks.co has NOT BEEN COMPENSATED for coverage of HTFL. TopStockPicks.co and its affiliates or officers may buy and sell shares of HTFL in the open market at any time without notice. TopStockPicks.co does not set price targets on securities. Always do your own due diligence and consult your financial advisor. Never invest into a stock discussed by TopStockPicks.co unless you can afford to lose your entire investment.
